John J.P. Kastelein, MD PhD FESC Dr. Kastelein (1954) is Emeritus Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he held the Strategic Chair of Genetics of Cardiovascular Disease. Professor Kastelein has published over 890 research papers in peer reviewed journals, including Nature Genetics, Lancet, New England Journal of Medicine, JAMA and Circulation and has a Hirsch index of 130 in February 2019. His citations reached over 7000 in 2020 and in total over 80.000 Source: Web of Science John J.P. Kastelein is currently an operating partner at Forbion Capital Management, Naarden, the Netherlands, with a specialized focus on cardiometabolic disease. He is CSO of NewAmsterdam Pharma and acting chief medical officer (CMO) of Statin Biotechnology Inc., a company developing a monoclonal antibody (Mab) against apolipoprotein CIII .